National Hemophilia Foundation (NHF) - Exhibit Hall
Back to Exhibit Hall / Tremeau Pharmaceuticals
Tremeau Pharmaceuticals
Tremeau is focused on developing non-opioid pain therapies for people with significant unmet need. Our lead clinical stage product, TRM-201 (rofecoxib), is a COX-2 selective NSAID and a non-opioid analgesic. We plan to initiate a Phase III trial for TRM-201 for the treatment of hemophilic arthropathy later this year.
Click HERE for Tremeau Pharmaceuticals’ QR code
